AQR Capital Management LLC Buys 94,703 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

AQR Capital Management LLC raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 517.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,020 shares of the company’s stock after purchasing an additional 94,703 shares during the period. AQR Capital Management LLC owned 0.13% of Day One Biopharmaceuticals worth $1,557,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Day One Biopharmaceuticals by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock valued at $33,575,000 after acquiring an additional 336,281 shares during the last quarter. Estuary Capital Management LP lifted its holdings in shares of Day One Biopharmaceuticals by 82.5% in the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company’s stock valued at $26,616,000 after acquiring an additional 728,240 shares during the last quarter. Parkman Healthcare Partners LLC lifted its holdings in shares of Day One Biopharmaceuticals by 34.2% in the 4th quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company’s stock valued at $9,136,000 after acquiring an additional 159,341 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at about $7,387,000. Institutional investors own 87.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on DAWN. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the company from $11.00 to $24.00 in a report on Thursday, August 1st. JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Piper Sandler reissued an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Needham & Company LLC increased their price objective on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN opened at $13.53 on Friday. The firm has a market cap of $1.18 billion, a PE ratio of -5.39 and a beta of -1.51. The firm’s 50 day simple moving average is $13.88 and its 200-day simple moving average is $14.44. Day One Biopharmaceuticals, Inc. has a one year low of $9.67 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The company had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $0.90 million. Equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 3,202 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $44,828.00. Following the transaction, the general counsel now directly owns 26,928 shares of the company’s stock, valued at approximately $376,992. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $44,828.00. Following the transaction, the general counsel now directly owns 26,928 shares in the company, valued at approximately $376,992. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,748 shares of company stock valued at $1,009,272. 8.40% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.